Biognosys and Michael J. Fox Foundation Partner to Develop Parkinson’s Disease Biomarkers
The collaboration focuses on creating sensitive assays for a common genetic risk factor to guide drug development and clinical trials.
Read MorePosted by CLP Edit Staff | Apr 15, 2026 | Company News, Lab Management, Mass Spectrometry |
The collaboration focuses on creating sensitive assays for a common genetic risk factor to guide drug development and clinical trials.
Read MorePosted by CLP Edit Staff | Apr 14, 2026 | Company News, Mass Spectrometry, Mass Spectrometry Instruments |
The collaboration will use multi-omic platforms and AI-driven analytics to identify disease patterns and improve patient stratification within the PRECISE-SG100K study.
Read MorePosted by CLP Edit Staff | Apr 14, 2026 | Cancer, Company News, Diagnostic Technologies |
The collaboration aims to create an innovation pipeline for specialized pediatric tests across oncology, metabolic disease, and autoimmune conditions.
Read MorePosted by CLP Edit Staff | Apr 13, 2026 | Diagnostic Technologies, Immunoassay |
The diagnostic tool identifies a specific biological cause of autism with more than 97% predictive accuracy.
Read MorePosted by CLP Edit Staff | Apr 13, 2026 | Company News, Flu & Respiratory Infections, Immunoassay |
The high-throughput host-response assay provides results in approximately 20 minutes to help guide treatment decisions and antimicrobial stewardship.
Read More